Approaches in psoriasis therapy are mainly focused on inhibiting immune signaling such as TNF-α, IL-17, IL-12/IL-23 [42,43], BTK [32,35], and other tyrosine kinases [44]. This evidence concerns the gene IL17A and psoriasis.